內克塔治療 NKTR 深 滬
等待開盤 03-26 09:30:00 美东时间
72.08
-0.880
-1.21%
華盛通- 最 高77.9699
- 今 開73.65
- 成交量 102.21万股
- 最 低 70.86
- 昨 收 72.96
- 總市值 20.17亿
- 52周最高 77.9699
- 市盈率 靜 --
- 換手率 3.65%
- 52周最低 6.48
- 委 比 -31.60%
- 總股本 2797.95万
- 歷史最高 1670.40
- 量 比 1.51
- 振 幅 9.74%
- 歷史最低 6.189
- 每 手 1
- 風險率 21.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Nektar rezpegaldesleukin Phase 2b data set for two oral presentations at AAD annual meeting
Nektar rezpegaldesleukin Phase 2b data set for two oral presentations at AAD annual meeting Nektar will attend the American Academy of Dermatology Annual Meeting on March 27-31, 2026 in Denver, Colorado. Data from a Phase 2b study of rezpegaldesleukin in severe-to-very-severe alopecia areata will be
03-20 22:00
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $123
Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $102 to $123.
03-17 00:37
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monday
03-16 18:00
Nektar Therapeutics Bets Big on Respag Phase 3
Nektar Therapeutics (($NKTR)) has held its Q4 earnings call. Read on for the ma...
03-14 08:04
Nektar Therapeutics jumps on Q4 results
Nektar Therapeutics (NKTR) is up 6% during early-trading hours on Friday after the biopharmaceutical company beat fourth-quarter revenue and EPS estimates. For the fourth quarter, the company reported...
03-13 22:39
财报速睇 | 内克塔治疗 2025财年年度营收0.55亿美元，同比下降43.9%；归母净利润亏损1.64亿美元，同比亏损扩大37.8%
华盛资讯3月13日讯，内克塔治疗公布2025财年年度业绩，公司年度营收0.55亿美元，同比下降43.9%，归母净利润亏损1.64亿美元，同比亏损扩大37.8%。
03-13 18:31
财报速睇 | 内克塔治疗 2025财年Q4营收0.22亿美元，同比下降24.1%；归母净利润亏损0.36亿美元，由盈转亏
华盛资讯3月13日讯，内克塔治疗公布2025财年Q4业绩，公司Q4营收0.22亿美元，同比下降24.1%，归母净利润亏损0.36亿美元，由盈转亏。
03-13 06:32
Nektar Therapeutics Q4 EPS $(1.78) Beats $(2.59) Estimate, Sales $21.807M Beat $10.404M Estimate
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(2.59) by 31.27 percent. This is a 442.31 percent decrease over earnings of $0.52 per share
03-13 04:17
